Investigation of serum biomarker for prediction of efficacy of the treatments for inflammatory bowel disease
Not Applicable
- Conditions
- Inflammatory bowel diseases(ulcerative colitis, crohn's disease), intestinal Behcet disease
- Registration Number
- JPRN-UMIN000014201
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
In patients with inflammatory bowel diseases (IBD), alterations of oligosaccharide structures of IgA or IgG can serve as diagnostic biomarkers of IBD. Serum leucine-rich alpha-2 glycoprotein was associated with clinical and endoscopic activity of IBD and can serve as a new biomarker for monitoring disease activity of IBD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 129
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with mental diseases 2) Patients younger than 16 years old. 3) Patients who are not suitable to attend this study judged by physicians.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The titers of biomarkers(serum oligosaccharides in immunoglobulins and cytokines)
- Secondary Outcome Measures
Name Time Method